Clinical Trial

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Study acronym: ZAMBONI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-28
notable Primary completion pushed: 2029-02-28 -> 2029-04-30 2026-07-28
minor Completion pushed: 2030-02-28 -> 2030-04-30 2026-07-28
Trial Details
NCT Number NCT07043608
Lead Sponsor Kelly Fitzgerald, MD
Collaborators: Exelixis
Conditions Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer +2 more
Enrollment 20 participants
Start Date 2026-06-10
Primary Completion 2029-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-27